Search

A new paper from MSK physician-scientist Luis Diaz presents the evidence on which the FDA approved the immunotherapy drug pembrolizumab for cancers with a specific genetic abnormality.

By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.

For the first time, scientists have shown that the gene APC, which is mutated in the vast majority of colorectal cancers, might be a promising target for future therapies.